Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
24
CLDI Quote, Financials, Valuation and Earnings
Last price:
$1.36
Seasonality move
:
-32.48%
Day range:
$1.28 - $1.38
52-week range:
$1.10 - $19.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.41x
Volume:
69.8K
Avg. volume:
136.8K
1-year change:
-92.18%
Market cap:
$9.7M
Revenue:
--
EPS (TTM):
-$6.74
Analysts' Opinion
-
Consensus RatingCalidi Biotherapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $10.00, Calidi Biotherapeutics, Inc. has an estimated upside of 8723.88% from its current price of $1.36.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $10.00 representing 100% downside risk from its current price of $1.36.
Fair Value
-
According to the consensus of 1 analyst, Calidi Biotherapeutics, Inc. has 8723.88% upside to fair value with a price target of $10.00 per share.
CLDI vs. S&P 500
-
Over the past 5 trading days, Calidi Biotherapeutics, Inc. has underperformed the S&P 500 by -6.95% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Calidi Biotherapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Calidi Biotherapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Calidi Biotherapeutics, Inc. reported revenues of --.
Earnings Growth
-
Calidi Biotherapeutics, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Calidi Biotherapeutics, Inc. reported earnings per share of -$2.21.
Enterprise value:
2.9M
EV / Invested capital:
0.27x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-0.13x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$1.6M
Return On Assets:
-217.81%
Net Income Margin (TTM):
--
Return On Equity:
-1476.9%
Return On Invested Capital:
-350.65%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$736K | -$1.5M | -$1.6M | -$390K | -$427K | |
| Operating Income | -$23.9M | -$27.6M | -$19.8M | -$5.2M | -$5M | |
| EBITDA | -$23.1M | -$26.1M | -$18.2M | -$4.8M | -$4.6M | |
| Diluted EPS | -$370.29 | -$5.81 | -$6.74 | -$0.06 | -$2.21 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2M | $479.1K | $11.7M | $2.2M | $11M | |
| Total Assets | $232M | $42.2M | $18.6M | $6.7M | $14M | |
| Current Liabilities | $47.9K | $1.3M | $10.9M | $11.6M | $5.2M | |
| Total Liabilities | $21M | $10.4M | $19.7M | $16.5M | $6.8M | |
| Total Equity | $211M | $31.8M | -$1.1M | -$9.8M | $7.2M | |
| Total Debt | -- | -- | $6.9M | $7.6M | $2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$25.7M | -$19.5M | -$21.7M | -$4.9M | -$4.2M | |
| Cash From Investing | -$604K | -$46K | $1.9M | -$6K | -$27K | |
| Cash From Financing | $36.3M | $11.3M | $28.2M | $6M | $9.5M | |
| Free Cash Flow | -$26.3M | -$19.5M | -$21.8M | -$5M | -$4.3M | |
CLDI
Sector
Market Cap
$9.7M
$28.3M
Price % of 52-Week High
7.08%
51.3%
Dividend Yield
0%
0%
Shareholder Yield
-259.57%
-1.42%
1-Year Price Total Return
-92.18%
-17.78%
Beta (5-Year)
--
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.37
200-day SMA
Sell
Level
$4.06
Bollinger Bands (100)
Sell
Level
0.61 - 3.61
Chaikin Money Flow
Sell
Level
-50.5M
20-day SMA
Sell
Level
$1.42
Relative Strength Index (RSI14)
Sell
Level
43.96
ADX Line
Sell
Level
12.72
Williams %R
Neutral
Level
-63.3333
50-day SMA
Sell
Level
$1.49
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Neutral
Level
78.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-15.8477)
Sell
CA Score
(Annual)
Level (-12.1455)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (12.1792)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Calidi Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in stem cell-based platforms to revolutionize oncolytic virotherapies. The company was founded in 2014 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, CLDI has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CLDI average analyst price target in the past 3 months is $10.00.
-
Where Will Calidi Biotherapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Calidi Biotherapeutics, Inc. share price will rise to $10.00 per share over the next 12 months.
-
What Do Analysts Say About Calidi Biotherapeutics, Inc.?
Analysts are divided on their view about Calidi Biotherapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Calidi Biotherapeutics, Inc. is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is Calidi Biotherapeutics, Inc.'s Price Target?
The price target for Calidi Biotherapeutics, Inc. over the next 1-year time period is forecast to be $10.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CLDI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Calidi Biotherapeutics, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of CLDI?
You can purchase shares of Calidi Biotherapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Calidi Biotherapeutics, Inc. shares.
-
What Is The Calidi Biotherapeutics, Inc. Share Price Today?
Calidi Biotherapeutics, Inc. was last trading at $1.36 per share. This represents the most recent stock quote for Calidi Biotherapeutics, Inc.. Yesterday, Calidi Biotherapeutics, Inc. closed at $1.36 per share.
-
How To Buy Calidi Biotherapeutics, Inc. Stock Online?
In order to purchase Calidi Biotherapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CLDI Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CLDI
Sector
P/E ratio
--
23.99x
PEG ratio
-0.01x
-0.01x
P/B ratio
1.41x
1.80x
Price / LTM sales
--
1.59x
Growth Metrics
CLDI
Sector
Revenue growth
--
4.62%
Earnings growth
-3313.93%
10.71%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.10
-$0.20
Profitability
CLDI
Sector
Profitability FY 2024
-$1.5M
$3.6M
Return on invested capital
-350.65%
-31.84%
Return on assets
-217.81%
-27.96%
Return on equity
-1476.9%
-37.47%
Earnings Date
Last Earnings Date
Dec
20
Next Earnings Date
Dec
20
Estimated Next Earnings Date
Mar
21
Balance Sheet
CLDI
Sector
Total cash
$10.5M
$26.4M
Short term investments
--
$25.7M
Total assets
$14.2M
$78M
Long term debt
$2M
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
